The goal of this clinical trial is to determine if triple inhaled therapy with Budesonide/Glycopyrronium/Formoterol (BGF) and Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) are effective in treating patients with stable chronic obstructive pulmonary disease (COPD). It will also assess the safety of both drugs. The main questions it aims to answer are: * Does BGF demonstrate a comparable effect to FUV in COPD participants? * What medical problems do participants experience when taking BGFand FUV?
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Changes in airway resistance at 5 Hz (R5) on COPD patients
Timeframe: From enrollment to the end of treatment at 8 weeks
Changes in airway resistance at 20 Hz (R20) on COPD patients
Timeframe: From enrollment to the end of treatment at 8 weeks
Difference of airway resistance between 5 Hz and 20 Hz (R5-R20) on COPD patients
Timeframe: From enrollment to the end of treatment at 8 weeks
Reactance at 5 Hz (X5) on COPD patients
Timeframe: From enrollment to the end of treatment at 8 weeks